Beta-blockers

Beta-blockers na-eji dị ka antihypertensive ọgwụ kemgbe mmalite sixties. Ebe ọ bụ na nchọpụta nke mbụ pụta nke ọgwụgwọ na ụbọchị nke ịdị irè ha na-ọma akwukwo na ọtụtụ na-achịkwa ọmụmụ, nakwa dị ka tụnyere mmetụta nke ndị ọzọ nke oge a.

Beta-blockers na-eji ihe ịga nke ọma na ala ọbara mgbali ma gbochie mmepe nke ọrịa obi na enwe. The usoro nke ha antihypertensive edinam dabeere na Mbelata ke gbasara obi mmepụta ruru ka a Mbelata nke ike na ugboro ole nke contractions. Ke adianade do, beta-blockers eme ka suppression nke secretion nke renin na juxtaglomerular (okoloklubochkovom) akụrụ ngwa na nke a, n'ụzọ dị irè-ebelata ọrụ nke renin-angiotenzinaldosteronovoy na etiti vasomotor usoro.

Ha ruo ogologo oge iji pụrụ ịkpasu a ọnụ nke vaskụla eguzogide (ngụkọta elu), n'ihi na ụba baroreceptor uche na mmepụta ke vaskụla mgbidi prostacyclin (prostaglandin vasodilating).

Dị iche iche na beta-blockers eji na Ẹkot doses, nwere a yiri hypotensive mmetụta. Full antihypertensive mmetụta amalite n'ime abụọ na izu anọ. "Kagbuo" syndrome nwere ike ime megide ndabere nke ogologo oge ọgwụgwọ. N'ihi ya mgbochi ọgwụ na-adịghị akwụsị ozugbo, na-eji nwayọọ nwayọọ belata dose maka iri na iri na iri na anọ na ụbọchị.

Systemic n'ebe ọgwụ ọjọọ, karịsịa ndị na-abụghị nhọrọ, pụrụ ịkpasu mmepe nke clinically ịrịba gbasara obi na noncardiac mmetụta.

The mbụ gụnyere ọrịa na-emetụta akparamàgwà mmadụ obi ndabere (ịda mbà n'obi, nsogbu ihi ụra, wdg), akụkụ okuku ume na mgbaàmà (bronchospasm), elu vasoconstriction (intermittent claudication, oyi na nsọtụ, wdg), muscle adịghị ike, adịghị ike. Extracardiac mmetụta na-anọchi anya impairment nke gbasara akụrụ ọrụ mere site belata ọbara na akụrụ, ihe isi ike na lipid na carbohydrate metabolism.

Na gbasara obi ngosipụta otu na-agụnye:

• gbasara obi pumping ọrụ iro so na mgbaàmà nke erughi;
• mgbochi (atrioventricular sinoatrialnaya) obi na bradycardia;
• hypotension megide oké ọnụ ke ọbara mgbali;
• antiarrhythmic mmetụta.

Ọ ga-kwuru na a dịgasị iche iche nke pharmacological Njirimara blocker-enye gị ohere iji họrọ ezigbo ọgwụ fọrọ nke nta ọ bụla ikpe. Nke a na-na tolerability nke ọgwụgwọ, nke kasị ala n'ihe ize ndụ nke oghom ihe, oge nke ikpughe na ụdị na-adakarị ọnọdụ.

Oge akara aka nke beta-blockers ka a ọbụ ọgwụ na-enye ohere maka normalisation nke ọbara mgbali na ihe 40-50% nke ọrịa na ọbara mgbali. Tụnyere mmetụta na ọrịa na-eto eto, n'etiti na ndị okenye afọ, mmetụta dịtụ ala na ndị agadi. The ojiji nke thiazide diuretics na Nchikota na a beta-blocker eliminates iche. N'ihi ya, ịdị irè nke ọgwụgwọ ndị dị otú ahụ a Nchikota enwekwu na 78-80%.

Beta-blockers na -emeso rịaworo ogide a pụrụ iche ebe. Na ọrịa a, ndị dị otú ahụ ọgwụ ọjọọ eme ihe na-eji dị ka Anaprillin (obzidan), Sotalol, Atenolol, Konkor, Monotard.

Mmetụta nke ndị a niile ọgwụ ọjọọ eme ihe iji na mbenata ọbara mgbali na "deceleration" obi ọnụego. The onunu ogwu nke ọ bụla ọgwụ a ga-ahọrọ kpere onye dibịa.

Ọgwụ ọjọọ na-contraindicated na ụkwara ume ọkụ, ala ala okpo akpa ume ọrịa, atrioventricular ngọngọ abụọ ma ọ bụ atọ ogo. Ọ bụghị na-atụ aro iji ihe beta-blockers na mkpọchị glucose ndidi, elu ọrịa akwara, na-eme egwuregwu na n'anụ ahụ nọ n'ọrụ ndị mmadụ n'otu n'otu.